UPSHER-SMITH LABORATORIES

Bora Pharmaceuticals acquires US-based Pyros Pharmaceuticals, known for developing Vigafyde, a treatment for infantile spasms. Vigafyde, approved by the FDA, is the first new product for this condition in 15 years, offering a simple dosing process. Bora aims to enhance treatment satisfaction and patient outcomes.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.